{"id":125776,"title":"genedrive PLC (AIM: GDR) Expects Revenue to Double as Commercial Momentum Builds","publisher":"Share Talk","author":"sharetalk","published":"2025-08-11T08:14:55+00:00","modified":"2025-08-11T08:14:55+00:00","canonical_url":"https://www.share-talk.com/genedrive-plc-aim-gdr-expects-revenue-to-double-as-commercial-momentum-builds/","markdown_url":"https://www.share-talk.com/genedrive-plc-aim-gdr-expects-revenue-to-double-as-commercial-momentum-builds.md","json_url":"https://www.share-talk.com/genedrive-plc-aim-gdr-expects-revenue-to-double-as-commercial-momentum-builds.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["Antibiotic","biological","blood clots","chemistry","coronavirus","COVID-19","COVID19","David Budd","diagnostics","GDR","Genedrive","Genedrive Kit","Genedrive PLC","Greater Manchester","hospital","infectious diseases","lab testing","Manchester","Matthew Fowler","molecular","MT-RNR1 ID Kit","NHS","Royal Albert Edward Infirmary","Royal Bolton Hospital","SARS-COV-2","Share Talk","Stepping Hill Hospital","Tameside General Hospital","The Royal Oldham Hospital","UK hospitals"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/12/Genedrive.jpg?fit=1200%2C800&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Genedrive PLC (AIM: GDR),** the developer of rapid genetic testing technology, expects total income for the year ended 30 June to rise to around **£1 million**, up from **£0.5 million** a year earlier.\n\nThe increase was driven by[stronger second-half sales](https://www.investegate.co.uk/announcement/rns/genedrive--gdr/trading-update/9042109) of **£0.65 million**, compared with **£0.35 million** in the first half. Overheads were stable, with a greater focus on targeted commercial activity.\n\nThe company has visibility on approximately **£0.6 million** in early income for the current financial year, supported by key developments:\n\n-\nCompletion and submission of evidence to **NICE** for its Early Value Assessment, potentially unlocking wider UK adoption.\n\n-\nScotland’s phased national rollout of two Genedrive tests from around October.\n\n-\nLaunch of a 12-month rapid genotyping programme at **Manchester University NHS Foundation Trust**.\n\nInternationally, sales in **Europe** and the **Middle East** are gaining traction, while the **US** remains a priority market. FDA regulatory work is ongoing for its MT-RNR1 and CYP2C19 test kits, with the latter’s submission expected early next year.\n\nCash balances stand at around **£700,000**, and the board is reviewing financing options to bolster working capital.\n\nGenedrive welcomed planned NHS reforms in England that will expand the **NICE** appraisal pathway and introduce an ‘innovator passport’ from April 2026, aimed at accelerating uptake of medical technologies.\n\nCEO **Dr Gino Miele** said the company’s platform delivers improved patient outcomes, productivity gains for healthcare providers, and cost savings for the NHS. He also noted increasing traction in **Italy, the Netherlands, UAE, Bahrain, Kuwait, Saudi Arabia, and Qatar**."}